Urologist at Rochester Urology,PC
Urology
Dr. Robert A. Badalament, MD
|
|
Give Review
Robert Badalament works in the field of Urology. He graduated from Emory University School of Medicine. Emory University School of Medicine has a rank of 23 in research and a 42 in primary care He has 4 awards "Fellow (FACS)", "Super Doctor", "Most Compassionate Doctor" and "Top MD". Doctor Robert A. Badalament, MD is a published doctor. He has 81 papers published. The most current publication "Pharmacodynamics of doxorubicin in human bladder tumors." Robert A. Badalament, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Focal prostate cryoablation: initial results show Cancer control and potency preservation.
- In treating localized prostate Cancer the efficacy of cryoablation is independent of DNA ploidy type.
- Salvage cryosurgery for recurrent prostate Cancer after radiation therapy: a seven-year follow-up.
- Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate Cancer.
- Is radical Prostatectomy primarily a surgical debulking procedure?
- Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in Bladder tissues and tumors.
- Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
- Patient-reported complications after cryoablation therapy for prostate Cancer.
- Cryosurgery for prostate Cancer: improved glandular ablation by use of 6 to 8 cryoprobes.
- Pharmacodynamics of doxorubicin in human Bladder tumors.
- Multicenter radioimmunoscintigraphic evaluation of patients with Prostate carcinoma using indium-111 capromab pendetide.
- Is the role of cystoscopy in the detection of Bladder cancer really declining?
- Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.
- Treatment of superficial Bladder cancer with intravesical chemotherapy.
- Cryosurgery of prostate Cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
- An algorithm for predicting nonorgan confined prostate Cancer using the results obtained from sextant core biopsies with prostate specific antigen level.
- Bladder cancer. Current diagnostic methods and treatment options.
- More is simply more and not necessarily better.
- Penetration of intravesical doxorubicin in human Bladders.
- Testicular torsion and its effects on contralateral testicle.
- Radioimmunoguided radical Prostatectomy and lymphadenectomy.
- Consensus review of the clinical utility of DNA cytometry in Bladder cancer. Report of the DNA Cytometry Consensus Conference.
- Fertility issues associated with testicular Cancer.
- Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial Bladder cancer.
- Penetration of mitomycin C in human Bladder.
- Pharmacokinetics of intravesical doxorubicin in superficial Bladder cancer patients.
- Transitional cell carcinoma: a common sense approach.
- Correlation of human Bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology.
- Histocultures of human Prostate tissues for pharmacologic evaluation.
- Sextant Prostate biopsies. A histopathologic correlation with radical Prostatectomy specimens.
- Cryoablation of the Prostate.
- Monitoring intravesical bacillus Calmette-Guerin treatment of superficial Bladder carcinoma by serial flow cytometry.
- Conservative management of epidermoid cyst of testis.
- Monitoring intravesical bacillus Calmette-Guerin treatment of superficial Bladder carcinoma by postoperative urinary cytology.
- Monitoring endoscopic treatment of superficial Bladder carcinoma by postoperative urinary cytology.
- Flow cytometric analysis of primary adenocarcinoma of the Bladder.
- The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial Bladder carcinoma.
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial Bladder cancer.
- Bacillus Calmette-Guérin therapy alters the progression of superficial Bladder cancer.
- Detection of carcinoma in the post-cystectomy urethral remnant by flow cytometric analysis.
- The sensitivity of Bladder wash flow cytometry, Bladder wash cytology, and voided cytology in the detection of Bladder carcinoma.
- The relative value of cytometry and cytology in the management of Bladder cancer: the Memorial Sloan-Kettering Cancer Center experience.
- Chemotherapy and vitamin E in treatment of Nb rat Prostate tumors.
- Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
- Superficial Bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
- Transrectal ultrasonography. Early experience with use as prostate Cancer detection tool.
- Advances in the diagnosis and management of Bladder cancer: flow cytometry, intravesical bacillus Calmette-Guerin, and systemic chemotherapy.
- Use of transrectal ultrasound in detection of prostatic carcinoma: a preliminary report.
- Coumarin necrosis of the penis.
- Radical nerve-sparing Prostatectomy: the first 30 patients treated with epidural anesthesia.
- Detection of Bladder carcinoma in females by flow cytometry and cytology.
- Noble PRST-1 Ca Prostate adenocarcinoma study on noble rats: preliminary study on new androgen sensitive tumor.
- Radiotherapy and concomitant chemoradiotherapy in the NB rat Prostate adenocarcinoma model.
- Bladder wall calcification after intravesical mitomycin C treatment of superficial Bladder cancer.
- Correlation of prostatic specific antigen with Gleason grade in prostate Cancer.
- Relative value of Prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of Prostate. Ohio State University experience.
- Prognostic factors in patients with primary transitional cell carcinoma of the upper urinary tract.
- Surgical treatment of brain metastases from Renal cell carcinoma.
- Flow cytometric analysis of primary and metastatic Bladder cancer.
- Colon carcinoma associated with ureterosigmoidostomy.
- Bladder cancer. What's new in diagnosis and treatment?
- Radical nerve-sparing Prostatectomy with epidural anaesthesia in 100 patients.
- Localized staging of Prostate carcinoma: comparison of transrectal ultrasound and magnetic resonance imaging.
- DNA ploidy analysis of invasive Bladder cancer by flow cytometry.
- Voided urine flow cytometry in screening high-risk patients for the presence of Bladder cancer.
- Pharmacokinetics of intravesical mitomycin C in superficial Bladder cancer patients.
- Bladder wall penetration of intravesical mitomycin C in dogs.
- Pharmacodynamics of mitomycin C in cultured human Bladder tumors.
- A method to study drug concentration-depth profiles in tissues: mitomycin C in dog Bladder wall.
- Cultured human Bladder tumors for pharmacodynamic studies.
- Paraganglioma of urethra.
- Enhancement of bacillus Calmette-Guerin attachment to the urothelium by removal of the rabbit Bladder mucin layer.
- Radical Prostatectomy: OSU and affiliated hospitals' experience 1985-1989.
- Two year experience with transrectal Prostate ultrasound.
- DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate Cancer.
- Radical Prostatectomy 1972-1987 single institutional experience: comparison of standard radical Prostatectomy and nerve-sparing technique.
- Prostate Cancer. Promising advances that may alter survival rates.
- Recurrent or aggressive Bladder cancer. Indications for adjuvant intravesical therapy.
- Computed tomography of primary transitional cell carcinoma of upper urinary tracts.
- Penile Cancer. Clinical presentation, diagnosis, and staging.
Schools
Emory University
Procedures Preformed
- Complete Nephrectomy With Robotic Assistance
- Cystectomy
- Cystometry
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- View All
Conditions Treated
- Balanoposthitis
- Bladder Atony
- Bladder Cancer
- Bladder Infection
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Fellow (FACS)
- Super Doctor
- Most Compassionate Doctor
- Top MD
Education
-
Memorial Sloan-Kettering Cancer Center -
Henry Ford Hospital - Wayne State University -
Emory University School of Medicine
Hospital
-
Crittenton Hospital Medical Center
Drug Facts
| NPI NUMBER | 1003829201 | |
| NPPES Provider LastName | BADALAMENT | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 483076900 | |
| NPPES Provider State | MI | |
| Specialty Description | Urology | |
| Total Claim Count | 2353.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 106.0 | |
| Percent Opioid Claims | 4.5 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003829201 |
| Last Name Of The Provider | BADALAMENT |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Brian D. Seifman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Relle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael D. Lutz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony D. Dimatteo, DO |
|
|
Dr. Jeffrey L. Weingarten, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey L. Weignarten, MD |
|
|
Atul D. Rajpurkar, MB
This Doctor is OpenDoctor Recommended.
|
|
|
John Addington, PA-C
This Doctor is OpenDoctor Recommended.
|